AKArmaghan Kazeminejad

Armaghan Kazeminejad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Armaghan Kazeminejad has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy Evaluation of Luliconazole‐Loaded Nanostructured Lipid Carriers in Treatment‐Resistant Dermatophytosis: A Randomized Clinical Trial

    by Robab Ebrahimi Barogh, Seyed Ali Jeddi, Ghasem Rahmatpour Rokni, Hossein Mohammad Taghi Fam, Abbas Raeisabadi, Zahra Yahyazadeh, Seyyed Mobin Rahimnia, Pedram Ebrahimnejad, Eisa Nazar, Nasim Gholizadeh, et al.

    Background: Dermatophytosis is a common superficial fungal infection that is increasingly complicated by terbinafine (TRB)‐resistant strains, especially Trichophyton indotineae . Conventional antifungals often show limited efficacy against resistant isolates, highlighting the need for novel treatments. This study evaluated the efficacy and safety of nanostructured lipid carrier–loaded luliconazole (NLC‐LCZ) gel in TRB‐resistant dermatophytosis. Materials and Methods: In a randomized, clinical trial conducted at Touba Specialty Clinic, Sari, Iran, forty‐eight adults with confirmed TRB‐resistant dermatophytosis were assigned to oral itraconazole (ITZ), topical luliconazole, NLC‐LCZ gel, or ITZ + NLC‐LCZ gel for 4 weeks ( n = 12 each). The primary endpoint was complete recovery (clinical and mycological), while secondary endpoints included lesion size, itch, inflammation, Dermatology Life Quality Index (DLQI), and safety. Results: Complete recovery occurred in 83.3% of ITZ + NLC‐LCZ, 75% of NLC‐LCZ, 58.3% of LCZ, and 0% of ITZ alone. LCZ and NLC‐LCZ had lower MIC 50 / MIC 90 values (0.016 μg/mL) compared with ITZ (MIC 90 : 8 μg/mL) and TRB (MIC 90 : 4 μg/mL). DLQI improved most in NLC‐LCZ (score: 2) and ITZ + NLC‐LCZ (score: 3) groups ( p < 0.001). Adverse events were mild and did not require discontinuation. Conclusions: These findings indicate that NLC‐LCZ enhanced antifungal efficacy and quality of life in TRB‐resistant dermatophytosis, and that combination therapy with ITZ + NLC‐LCZ yielded the highest recovery, representing a promising strategy against resistant infections.

  • Open Access

    Arnebia euchroma Root Ointment for Pressure Ulcer Healing: A Double‐Blind Randomized Controlled Trial

    by Armaghan Kazeminejad, Ebrahim Salehifar, Zahra Faghih, Mohammad Malekan, Amirreza Espahbodi, Mohtaram Andalib, Masoomeh Abdi Talarposhti, Nasim Gholizadeh

    Background: Although various therapies are available for pressure ulcers, no single treatment has demonstrated superior effectiveness compared to others. Arnebia euchroma exhibits anti‐inflammatory properties that facilitate the healing of surgical wounds and burns. We aimed to evaluate the efficacy of A. euchroma root ointment for the treatment of pressure ulcers. Methods: This double‐blind randomized controlled trial included 20 patients with Stage I–III pressure ulcers from nursing homes and medical facilities in Sari, Mazandaran, Iran, in 2020‐2021. Patients were randomly assigned to two groups: Patients in the intervention group received Arnebia euchroma root 5% ointment, while those in the control group received silver sulfadiazine 1%. The primary outcome was improvement in the diameter and depth of the ulcer. Secondary outcomes were changed in the Pressure Ulcer Scale for Healing (PUSH) and side effects. Outcomes were assessed before intervention and then at one, two, three, and 4 weeks. Results: Patients in both groups were comparable in terms of age, sex, nutritional disorders, use of antibedsore mattress, disease duration, underlying diseases, pressure ulcer stage, and pain, as well as baseline ulcer diameter, depth, and PUSH score. After 4 weeks, the ulcer depth was significantly lower in the intervention group than that in the control group ( p < 0.001, standardized mean difference [SMD] = −2.43, 95% confidence interval [CI] −0.58; −1.23). Ulcer depth and diameter differences at other time points were not statistically significant. Mean PUSH scores did not differ significantly between groups at any time point. No side effects were observed in any of the patients. Conclusions: A. euchroma root ointment can significantly reduce pressure ulcer depth after 4 weeks of application, with no significant effects on ulcer diameter and PUSH score. A. euchroma root ointment appears to be a safe treatment for pressure ulcers. These results need to be confirmed in larger randomized controlled trials. Trial Registration: Iranian Registry of Clinical Trials (IRCT): IRCT20170818035762N4

  • Open Access

    The Therapeutic Effects of a Bentonite‐Based Facial Mask With Alcea sulphurea Extract on Acne Severity and Patient Experience: Add‐On Randomized Controlled Clinical Trial

    by Sara Salimi, Moloud Fakhri, Majid Saeedi, Seyyed Mobin Rahimnia, Armaghan Kazeminejad, Mahmood Moosazadeh, Emran Habibi, Assie Jokar

    Background: Acne vulgaris adversely impacts quality of life, requiring safer alternatives to conventional treatments. This study explores a facial mask combining Bentonite's detoxifying and Alcea sulphurea 's anti‐inflammatory properties, rooted in Traditional Persian Medicine (TPM). It aims to evaluate its efficacy in reducing acne severity and enhancing patient satisfaction, integrating traditional and modern therapeutic approaches. Methods: This add‐on randomized, controlled clinical trial included 60 patients with moderate acne, recruited through purposive sampling in Sari from October 2022 to November 2023. Participants were randomly allocated into intervention (Bentonite‐Alcea mask + Azithromycin 250 mg) and placebo (placebo + Azithromycin 250 mg). Outcomes, including lesion count, acne severity, and satisfaction, were assessed at baseline, 4 weeks, and 8 weeks. Data analysis was conducted using SPSS version 16. Results: Sixty people completed the study (30 persons in both group). The mean and standard deviation of the age in control group was 24 ± 8.03 years and in placebo group was 19.03 ± 7.03 and 46 subjects (76.7%) were female. TLC and ASI in the fourth and eighth weeks in control group were significantly less than in placebo group ( p < 0.001). The percentage of relatively satisfied and very satisfied participants in the intervention group was significantly higher than the control group ( p < 0.001). Bentonite‐based facial mask with Alcea sulphurea extract had no serious side effects. The intervention group exhibited significant reductions in TLC (total lesion count) (55.45% ± 21.74%) and ASI (Acne Severity Index) (66.33% ± 27.15%) from baseline to 8 weeks ( p < 0.001), outperforming the placebo group. Patient satisfaction was notably higher in the intervention group, with 43.3% being very satisfied compared to 3.3% in the placebo group ( p < 0.001). Conclusion: A facial mask based on Bentonite and A. sulphurea extract effectively reduces acne severity and enhances patient satisfaction. These findings suggest its potential as a natural alternative or adjunct to conventional acne treatments. Trial Registration: Iranian registry: IRCT20220403054395N1

  • Open Access

    Topical Formulation Based on Arnebia euchroma as a Novel Possible Efficient Treatment on Epidermolysis Bullosa Lesions: A Case Series of Fourteen Patients

    by Amirsaleh Abdollahi, Rouzbeh Kadkhodaee, Armaghan Kazeminejad, Lotfollah Davoodi, Muhammadreza Oraee Karimi, Alireza Razavi, Sobhan Mohebbi Najmabad

    BACKGROUND: Epidermolysis bullosa (EB) is a skin fragility disorder that results in the disruption of the dermo-epidermal junction and painful blisters on the skin and mucous membranes. Currently, there is almost no definite treatment for EB patients. AIM: This study aims to assess the effect of topical formulation based on Arnebia euchroma (AE) on lesions induced by EB. MATERIALS AND METHODS: All patients with EB diseases treated with Hochobeh ointment (AE+Beewax+Olive oil) in 2022 at our dermatological clinic were included in the study. EB diseases were diagnosed based on the following criteria: (1) clinical features (2) histopathological findings (3) Linear depositions of IgG, IgA, IgM 4. salt-split skin (SSS) or other immune serological tests compatible with the diagnosis of EB disease. Hochobeh ointment and lotion treatment were initiated. Clinical evaluations were repeated 3 and 7 days after the treatment began, and photographs were taken to document the changes in clinical severity. EB Disease Activity and Scarring Index (EBDASI) and EB Quality of Life (EB-QoL) questionnaires were used to assess the severity of EB and the quality of life, respectively. All statistical analyses were performed using statistical package for the social sciences version 16. RESULTS: Overall, fourteen patients were included. Improvement in clinical features, including reduction of infection and inflammation and improvement of wound healing, was observed. EBDASI and EB-QoL scores decreased significantly after treatment (91.5 ± 45.7 vs. 68.9 ± 43, p = 0.001; 24.6 ± 6.7 vs. 18 ± 5.2, p = 0.001, respectively). CONCLUSION: Hochobeh ointment may be effective in treating EB skin and mucosal lesions.


  • Open Access

    Topical Calcipotriol for the Treatment of Cutaneous Warts: An Assessor‐Blind Randomized Placebo‐Controlled Trial

    by Armaghan Kazeminejad, Arezoo Bodaghi, Zohreh Hajheydari, Mahmood Moosazadeh, Mohammadreza Rafati, Nasim Gholizadeh

    Background. Cutaneous warts are common epidermal proliferations caused by human papillomavirus (HPV). We aimed to determine the safety and efficacy of topical calcipotriol for the treatment of cutaneous warts. Methods. This assessor‐blind randomized placebo‐controlled trial included 56 patients with cutaneous warts referred to a dermatology clinic from January 21 to March 20, 2020. Patients were randomized into two groups (n = 28). One group received calcipotriol 0.05% ointment twice a day on the lesions with a uniform thickness of 1 mm, and the other group received a placebo. The duration of treatment was twomonths, which continued for another two months if resolution did not occur. The primary outcome was complete response to treatment evaluated four months after the initiation of therapy. Secondary outcomes were the number and size of warts assessed at 1, 2, and 4 months and adverse events, including erythema, pruritus, burning sensation, and scaling. Results. Patients in both groups were comparable regarding previous treatment, underlying disease, and disease duration. However, patients in the control group were older. Also, a higher proportion of patients in the calcipotriol group were male and had warts on their palms and toes. Moreover, a higher percentage of controls had moderate disease. The mean number and the size of lesions did not differ between groups before intervention; however, both were significantly lower in the calcipotriol group than in controls at 1st, 2nd, and 4th months. In addition, complete response to treatment was significantly higher in the calcipotriol group (85.7% vs. 16%; P < 0.001). On the other hand, the frequency of adverse events was not different between groups (P = 0.352). Conclusions. Calcipotriol can be considered a safe and effective treatment option for cutaneous warts. Trial Registration: This trial is registered with IRCT20170818035762N2, available at https://www.irct.ir/trial/45716.


  • Open Access

    Therapeutic Approaches of Infantile Acne: A Narrative Review Study

    by Armaghan Kazeminejad, Lotfollah Davoodi, Zohreh Hajheydari, Mohammad Jafar Ghahari

  • Open Access

    Comparative Efficacy of Fractional CO2 Laser and Q-Switched Nd:YAG Laser in Combination Therapy with Tranexamic Acid in Refractory Melasma: Results of a Prospective Clinical Trial

    by Amir Mohammad Beyzaee, Anant Patil, Mohamad Goldust, Marjan Moslemi, Armaghan Kazeminejad, Ghasem Rahmatpour Rokni

    Melasma manifests as hyperpigmented macules and patches, usually affecting the face, neck, and rarely upper limbs. This study evaluated comparative efficacy of a fractional CO2 laser with a Q-Switched Nd:YAG laser in combination therapy with tranexamic acid in refractory melasma. A total of 30 patients with refractory melasma were included in this study. The fractional CO2 laser (power: 30 w, pulse energy: 30 mJ, tip type: 300, pulse rate: 100/cm2) was used on one side of the patients’ face and three passes of the Q-Switched Nd:YAG (QSNY) laser (Wavelength: 1064 nm, pulse energy: 750 mJ, fluence: 1.50 J/cm2, spot size: 4 mm × 4 mm, hand piece: fractional) were used on the opposite side of the same patient’s face for six sessions. During the course of laser therapy, all patients received oral tranexamic acid 250 mg twice daily. Melasma area and severity index (MASI) score and physician’s satisfaction and patient’s satisfaction were analyzed. Thirty patients (mean age 39.97) were included. Patient global assessment (PtGA) in the fractional CO2 laser group was significantly better than the Q-Switched Nd:YAG laser group at 4th, 8th and 12th weeks (p-value < 0.001). According to PtGA, the improvement was significant in both groups over time. Physician global assessment (PGA) at the 8th and 12th weeks, and physician satisfaction (PS) at the 8th week, in the fractional CO2 laser group was significantly better than the Q-Switched Nd:YAG laser group (p-value < 0.05). The PGA in both groups significantly reduced over time. The MASI score significantly decreased in both groups over time. The MASI score in the fractional CO2 laser group decreased more than the Q-Switched Nd:YAG laser group over time (p < 0.001). The most common side effects reported were erythema and discomfort, which subsided in less than 24 h. A fractional CO2 laser with oral tranexamic acid is an effective and well tolerated therapeutic method for the treatment of patients with refractory melasma.


  • Treatment of Warts in Children With Focus on Recalcitrant Warts: A Narrative Review

    by Armaghan Kazeminejad, Mohammad Jafar Ghahari, Zohreh Hajheydari

    Context: Warts are benign cutaneous and mucosal growths caused by human papillomavirus. Warts are the most common skin diseases seen by pediatric dermatologists. Warts are often self-limited, especially in children, but some lesions are not resolved despite repeated treatments and referred to as recalcitrant warts. Evidence acquisition: Electronic databases such as Google Scholar, PubMed, and Scopus were searched during 2000-2018 and a review was conducted for articles published in English on pediatric warts by focusing on recalcitrant warts. Results: If warts are asymptomatic and being in a location that causes no cosmetic or other problems, observation is the ideal management course. Most parents and children prefer treatment for their warts. There are three modalities of treatment: medical, surgical, and immunotherapy. Conclusions: Treatment of warts is a therapeutic challenge that depends on the patient’s age and the type of warts. Despite treatment according to evidence-based guidelines, a significant proportion of warts are failed to respond. This condition is an unsolved problem in practice. The management for treating these lesions has remained unclear and a wide range of the second line of treatments has been developed.


  • Open Access

    Hydroxychloroquine-induced Stevens–Johnson syndrome in COVID-19: a rare case report

    by Lotfollah Davoodi, Hamed Jafarpour, Armaghan Kazeminejad, Eissa Soleymani, Zahra Akbari, Alireza Razavi

    The international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19) began in December 2019 that has affected >0.8 million individuals. Self-limiting respiratory tract involvement, severe pneumonia, multiorgan failure and death are the spectrum of COVID-19. To date, there are no especial therapeutic agents for COVID-19 infections. One such medication includes the antimalarial hydroxychloroquine (HCQ), which recently reported as a possible therapy for shortening the duration of COVID-19 symptoms, reducing inflammatory reactions to infection, impairing the exacerbation of pneumonia and boosting lung imaging findings. Like all medications, HCQ has side effects and may occur in COVID-19 patients. Here, we report on the case of a 42-year-old woman, presented with fever and dry cough, who had COVID-19 and 2 days later presented with a pruritic erythematous maculopapular rash, which started from the distal of upper extremities and rapidly, involved the entire body.


  • STAT3 ‐mutated hyperimmunoglobulin E syndrome with perianal skin tags and erosions: A case report

    by Regina Fölster‐Holst, Armaghan Kazeminejad, Ghasem Rahmatpour Rokni, Torello Lotti, Andy Goren, Mohamad Goldust

    Click on the book chapter title to read more.